SELLAS Life Sciences (SLS) EPS (Weighted Average and Diluted) (2011 - 2026)
SELLAS Life Sciences (SLS) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 28.57% year-over-year from -$0.04 in Q1 2025, and little changed on a QoQ basis from -$0.05 in Q4 2025.
SELLAS Life Sciences (SLS) has 13 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 28.57% year-over-year to -$0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.23 (up 39.47% YoY) and the FY2025 annual result came in at -$0.25, up 50.0% from the prior year.
- EPS (Weighted Average and Diluted) held at -$0.05 in Q1 2026 per SLS's latest filing, from -$0.05 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.05 in Q4 2025 and bottomed at -$1.05 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.21 (2024), against an average of -$0.26.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) plunged 556.25%; it then jumped 69.7% in 2024.
- Tracing SLS's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.43 in 2022, then jumped by 41.86% to -$0.25 in 2023, then soared by 68.0% to -$0.08 in 2024, then surged by 37.5% to -$0.05 in 2025, then declined by 0.0% to -$0.05 in 2026.
- Per Business Quant, the three latest SLS EPS (Weighted Average and Diluted) figures stand at -$0.05 (Q1 2026), -$0.05 (Q4 2025), and -$0.06 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.05 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -0.07 |
| Mar 31, 2025 | -0.07 |
| Dec 31, 2024 | -0.08 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.21 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.33 |
| Jun 30, 2023 | -0.31 |
| Mar 31, 2023 | -0.47 |
| Dec 31, 2022 | -0.43 |
| Sep 30, 2022 | -0.34 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -1.05 |
| Dec 31, 2021 | -0.42 |
| Sep 30, 2021 | -0.45 |
| Jun 30, 2021 | -0.30 |
| Mar 31, 2021 | -0.16 |
| Dec 31, 2020 | -0.28 |
| Sep 30, 2020 | -0.53 |
| Jun 30, 2020 | -0.66 |
| Jun 30, 2017 | -0.19 |
| Jun 30, 2016 | 0.58 |
| Jun 30, 2015 | -0.01 |
| Jun 30, 2013 | -0.11 |
| Jun 30, 2012 | -0.03 |
| Jun 30, 2011 | -0.10 |